WHO Chief Accuses Drugmakers Of Prioritizing Profits Above Sick, Elderly

GENEVA (AP) — The World Health Organization chief on Monday lambasted drugmakers’ profits and vaccine inequalities, saying it’s “not right” that younger, healthier adults in wealthy countries get vaccinated against COVID-19 before older people or health care workers in poorer countries and charging that most vaccine makers have targeted locations where “profits are highest.”

Director-General Tedros Adhanom Ghebreyesus kicked off the WHO’s week-long executive board meeting — virtually from its headquarters in Geneva — by lamenting that one poor country received a mere 25 vaccine doses while over 39 million doses have been administered in nearly 50 richer nations.

“Just 25 doses have been given in one lowest income country ― not 25 million, not 25,000 ― just 25. I need to be blunt: The world is on the brink of a catastrophic moral failure,” Tedros said. He did not specify the country, but a WHO spokeswoman identified it as Guinea.

“It’s right that all governments want to prioritize vaccinating their own health workers and older people first,” he said. “But it’s not right that younger, healthier adults in rich countries are vaccinated before health workers and older people in poorer countries. There will be enough vaccine for everyone.”

Tedros, an Ethiopian who goes by his first name, nonetheless hailed the scientific achievement behind rolling out coronavirus vaccines less than a year after the pandemic erupted in China, where a WHO-backed team has now been deployed to look into origins of the coronavirus.

“Vaccines are the shot in the arm we all need, literally and figuratively,” Tedros said. “But we now face the real danger that even as vaccines bring hope to some, they become another brick in the wall of inequality between the worlds of the world’s haves and have-nots.”

He noted the WHO-backed COVAX program, which aims to get vaccines out to all countries, rich or poor, based on need, has so far secured 2 billion vaccine doses from five producers and options on a billion doses more.

“We aim to start deliveries in February,” he said. “COVAX is ready to deliver what it was created for.”

That target date could be a tall order, because a key producer of vaccines for the developing world — the Serum Institute of India — has not confirmed a date and predicted that its rollout might not happen before March or April.

In his opening remarks, Tedros aired some of his toughest public words yet toward vaccine makers, criticizing “bilateral deals” between them and countries that the WHO says can deplete the effectiveness of the COVAX facility — and went further to raise the issue of profits.

“The situation is compounded by the fact that most manufacturers have prioritized regulatory approval in rich countries, where the profits are highest, rather than submitting full dossiers to WHO,” he said.

That appeared to allude to a shortage of data the U.N. health agency says it has received from vaccine makers so that the WHO can approve their shots for wider emergency use.

Dr. Clement Martin Auer, a board member from Austria, had sharp words and questions for GAVI, the Vaccine Alliance, that also with the Coalition for Epidemic Preparedness Innovations is leading the effort on COVAX.

While calling its principles of equal access to vaccines a “fantastic idea,” Auer faulted COVAX as being “slow” and unable to close “crucial numbers” of contracts. He defended the European Union, which counts among its 27 members many of the world’s richest countries, for getting vaccines for its 450 million citizens and being “the single largest donor” in supporting COVAX.

“We were, in the European Union, skeptical that GAVI-COVAX had the means and the capabilities to fulfill its tasks and negotiate the necessary contracts and to secure the needs of our citizens,” Auer said, adding that COVAX management had “rejected” proposals negotiated by GAVI and the EU.

He said GAVI-COVAX early last year had not included mRNA vaccines like those developed by Pfizer-BioNTech and Moderna in the COVAX portfolio.

“This was a major mistake, taking into account that the mRNAs are the early ones on the market and the gold standards when it comes to COVID vaccines,” Auer said.

The WHO has approved Pfzier-BioNTech for emergency use against coronavirus and could approve Moderna this week.

Dr. Bruce Aylward, a special adviser to Tedros, said that the WHO was in “detailed discussions with Pfizer. We believe very soon we will have access to that product.” He said the mRNA vaccines are “important” but are “extremely difficult” — alluding to cold-chain requirements, among other things, and are “extremely expensive.”

“What we are gunning for is to get 20% of the world, at least, vaccinated this year, and more ideally,” Aylward said. “We are in a strong position to move out with vaccines globally. We just need the assistance of our member states in particular to make sure that becomes the reality.”

In related vaccine news, Israel has struck a deal with Pfizer, promising to share vast troves of medical data with the international drug giant in exchange for the continued flow of its hard-to-get vaccine.

Proponents say the deal could allow Israel to become the first country to vaccinate most of its population, while providing valuable research that could help the rest of the world. But critics say the deal raises major ethical concerns, including possible privacy violations and a deepening of the global divide in access to coronavirus vaccines.

Due to the ultra-cold storage needed for the Pfizer vaccine, it is more expensive and harder to use than some rivals, including the Oxford-AstraZeneca vaccine, but studies show it is very effective. Israeli media have reported that Israel paid at least 50% more than other countries for the Pfizer vaccine.

Ashok Sharma in Delhi and Ilan Ben Zion in Jerusalem contributed to this report.